To assess prevention strategies for pneumococcal disease in Alaska, prospective surveillance during 1986-1990 identified 672 invasivepneumococcal infections, including 315 among Alaska Natives. Age-adjusted annual incidence was 74 per 100,000 for Alaska Natives and 16 per 100,000 for nonnatives. The annual incidence in Alaska Native children <2 years old was 624 per 100,000; rates of 84 per 100,000 for meningitis and 290 per 100,000 for bacteremic pneumonia were 8-10 times higher than for other US groups. By age 75, cumulative incidence (7%) and mortality (1%) in Alaska Natives were almost 4 times higher than for nonnatives. Only 17% of Alaska Native adults with predisposing conditions and invasive infections previously received pneumococcal vaccine. For Alaska Natives, a proposed heptavalent conjugate pneumococcal vaccine will include serotypes responsible for 85% of invasiveisolates from children <2 years but only 32% of those from adults. The 23-valent polysaccharide pneumococcal vaccine, which contains >94% of serotypes identified in Alaska Native toddlers and adults, should be used more widely.
To assess prevention strategies for pneumococcal disease in Alaska, prospective surveillance during 1986-1990 identified 672 invasivepneumococcal infections, including 315 among Alaska Natives. Age-adjusted annual incidence was 74 per 100,000 for Alaska Natives and 16 per 100,000 for nonnatives. The annual incidence in Alaska Native children <2 years old was 624 per 100,000; rates of 84 per 100,000 for meningitis and 290 per 100,000 for bacteremic pneumonia were 8-10 times higher than for other US groups. By age 75, cumulative incidence (7%) and mortality (1%) in Alaska Natives were almost 4 times higher than for nonnatives. Only 17% of Alaska Native adults with predisposing conditions and invasive infections previously received pneumococcal vaccine. For Alaska Natives, a proposed heptavalent conjugate pneumococcal vaccine will include serotypes responsible for 85% of invasiveisolates from children <2 years but only 32% of those from adults. The 23-valent polysaccharide pneumococcal vaccine, which contains >94% of serotypes identified in Alaska Native toddlers and adults, should be used more widely.
Despite the availability of antibiotics and a 23-valent pneumococcal polysaccharide vaccine, Streptococcus pneumoniae persists as a major cause of morbidity from meningitis, pneumonia, bacteremia, and otitis media in all age groups. Community-and hospital-based studies of bacteremia and pneumonia in developing [1] [2] [3] and developed countries [4] [5] [6] [7] [8] [9] [10] [11] have found a consistently high case-fatality rate for invasive pneumococcal infections. Mortality rates are highest in patients with underlying conditions for which vaccination is clearly indicated.
Unprecedented high incidence rates of invasive pneumococcal disease and meningitis were previously reported among an Eskimo population in southwestern Alaska [12, 13] , and currently, pneumonia is the leading diagnosis at hospital discharge for Alaska Native infants and children [14] . To determine the incidence of invasive pneumococcal disease throughout the entire Alaskan population and the likelihood of its prevention with the current polyvalent vaccine as well as pneumococcal protein conjugate vaccines under development [15] , we extended surveillance to include all Alaska Natives and nonnatives in the state of Alaska for a 5-year period, [1986] [1987] [1988] [1989] [1990] . We wanted to determine whether there were differences in pneumococcal dis-ease incidence between Alaska Natives and nonnatives living in close proximity in light of the growing evidence that minority populations in the United States are likely to experience a high burden of pneumococcal infections [5, [11] [12] [13] [16] [17] [18] .
Materials and Methods
Study population. Surveillance for invasive pneumococcal disease was conducted from January 1986 through December 1990 for all Alaska residents: whites (77%), Alaska Natives (16%, comprising Eskimos, Indians, and Aleuts). blacks (3.4%), Asians (1.8%), and other designations (1.7%). All 26 hospitals and one outpatient microbiology laboratory in Alaska provided pneumococcal isolates. Patients were also identified by a review of microbiology records and inpatient admission diagnoses.
Case definition and description. Invasive pneumococcal disease was defined as an acute illness associated with the isolation of S. pneumoniae from a normally sterile body site such as blood, cerebrospinal fluid, peritoneal fluid, or joint or pleural space. Pneumonia was defined by radiographic pulmonary infiltrates and acute clinical symptoms; meningitis and septic arthritis by a pneumococcal isolate from cerebrospinal fluid or joint effusion, respectively; and otitis media and cellulitis only by a clinician's diagnosis. Pneumococcal isolates forwarded to the Arctic Investigations Program were confirmed and serotyped by use of the Quellung reaction [19] . We compared the birth weights of children <3 years of age with invasive pneumococcal disease with those of all uninfected children statewide. All cases were matched to a statewide registry of patients with AIDS. Other underlying diseases and history of pneumococcal vaccination were available only for Alaska Natives.
Outcome. Cases were matched to mortality records, and death certificates were reviewed to determine the date and underlying cause of death. Death from pneumococcal disease was defined as immediate when it occurred within 7 days of the acquisition of the culture and delayed if it occurred 8-30 days later.
Statistical methods. Incidence rates were calculated for single and recurrent episodeswithin the surveillanceinterval. Population statistics used were estimates for 1988 interpolated from the 1980 and 1990 US census. For all ethnic groups and ages combined, the ratio of males to females was 1.08; however, the male-to-female ratio for those~65 years was 0.82. Differences in the disease rates between specific age strata of ethnic subgroups were compared by rate ratios, with 95% confidence intervals (CIs) calculated with a logarithmic transformation [20] .
Other differencesin variables were calculated using x 2 tests with Yates's corrections where appropriate. The rates ofpneumococcal disease in Alaska residents with AIDS were calculated per person-years of survival after the date of diagnosis of AIDS or 1 January 1986, whichever was later, through 31 December 1990. CIs assumed a Poisson distribution of cases.
Results
During the 5-year surveillance period, 672 episodes of invasive pneumococcal disease were diagnosed in 656 persons ranging in age from 1 day to 95 years. Hospital inpatients represented 72%of the cases, including a nosocomial rate of almost 2%. Although Alaska Natives make up only 16% of the total population of Alaska, 315 cases (47%) were among Alaska Natives and 357 were among nonnatives. Pneumococci were isolated from blood alone in 90% of all patients, from both blood and another sterile site in 5%, and only from a sterile site other than blood in 5%. There were 574 pneumococcal isolates received for confirmation, representing 83%ofall cases in Alaska Natives and 87%ofcases in nonnatives; 53 cases in Alaska Natives and 45 in nonnatives were identified by record review.
Disease distributionand incidence rates. The annual number of cases remained relatively constant but was lowest in July and August during the entire 5-year study period for nonnatives only (P < .0 1). No other consecutive annual, monthly, or seasonal trends were observed, even when examined by residence (rural vs. urban), age, or ethnicity.
For all ethnic groups, males <65 years of age were more likely to be infected (male-to-female ratio = 1.5). This did not hold true for older adults (male-to-female ratio = 0.8),
for whom the proportion of susceptible men had decreased.
The average annual incidence rate for invasive pneumococcal disease, age-adjusted to the 1980 US population, was 74 cases per 100,000 persons for Alaska Natives and 16 per 100,000 for nonnatives (table 1). This marked difference was observed for almost all age groups. For both ethnic groups, the highest rates occurred in children <2 years old, but Alaska Natives had a greater proportion of cases in this age group (40% vs. 33%, P < .05). For all children <2 years old, 76% of pneumococcal meningitis occurred during the first 6 months of life (figure 1), whereas all other types of pneumococcal invasive disease were more evenly distributed over the first 2 years (P < .00 1). The second highest age-specific rates were in adults~65, followed by adults 55-64 years of age (table 1). The derived cumulative incidence rate of disease for Alaska Natives living to age 75 years was 7%, >3.5 times higher than for non natives. Incidence rate ratios of Alaska Natives to non natives ranged from 2.1 for thosẽ 65 to 8.0 for those 40-54 years of age (table 1) . Geographic distribution. Age-specific incidence rates varied widely in different regions of Alaska (figure 2). The incidence of disease in Alaska Native children <2 years of age was highest in southwest and northwest Alaska. The incidence in adults in the interior and northwest regions exceeded that in all other regions for both Alaska Natives (relative risk = 3.5; 95% CI = 2.6-4.9) and nonnatives (relative risk = 1.7; 95% CI = 1.2-2.4); age-adjusted rates were 122 and 25 per 100,000 persons per year, respectively.
Presentation and disease-specific incidence rates. Pneumonia was the most frequent diagnosis among Alaska Natives (61 %) and non natives (53%), followed by bacteremia with no specified focus of infection among 15% ofAlaska Natives and 28% of nonnatives.
Annual incidence rates of pneumococcal meningitis and pneumonia in Alaska Native children <2 years of age were 8 and 10 times higher, respectively, than rates for nonnative children (table 2). In the Yukon-Kuskokwim Delta or southwest region, where high rates for Alaska Natives were found earlier [12] , the incidence rates during 1986-1990 for Alaska Native children <2 years of age were 145 per 100,000 for meningitis and 654 per 100,000 for pneumonia. Statewide, rates of pneumococcal meningitis and bacteremic pneumonia in Alaska Native adults were 7 and 5 times higher than corresponding rates in nonnatives.
Other clinical manifestations of pneumococcal bacteremia, including facial cellulitis and otitis media, were 4-5 times more frequent in Alaska Native children than in nonnatives. The annual rates of otitis media with pneumococcal bacteremia per 100,000 children <2 years of age, including otitis media with one or more additional presentations (n = 23), were 192 for Alaska Natives and 27 for nonnatives. Although rates of bacteremia without an identified focus of infection were higher for both young children and adults in Alaska Natives (table 2) than in non natives, the proportion of Alaska Natives <2 years old with bacteremia only was lower (16% vs. 42%, P < .0 1).
Recurrent disease. Recurrent episodes (n = 23) of invasive disease 1-66 months after the first, caused by either an unknown or different pneumococcal serotype of which only 1 was not included in the 23-valent polysaccharide pneumococcal vaccine, occurred in 16 patients during the 5-year surveillance period. For 6 other patients an additional episode either preceded or followed this interval. The rate of recurrent disease was 5% in Alaska Natives overall but only 2% in nonnatives (P = .05). Underlying diseases. One or more underlying diseases or conditions were identified for 59%of Alaska Native patients. Although 65% of Alaska Natives <2 years of age had no underlying diseases, the most common diagnoses in this age group were preexisting anemia (15%), chronic lung disease (7%), congenital defects (7%), and low birth weight «2500 g) or prematurity (7%) (table 3). The latter occurred in 7.4% of all patients <3 years of age compared with 4.8% of all births statewide from 1984 through 1990 (P = .08), and there were no differences between ethnic or birth cohorts. Of Alaska Native adults> 19 years of age with invasive infections, 85% had underlying diseases including alcoholism (59%), chronic lung disease (17%), and preexisting anemia (14%).
Invasive pneumococcal infections were diagnosed in five nonnative patients with AIDS. Thus, the attack rate of invasive pneumococcal disease in male nonnative AIDS patients 20-54 years of age was 3327 per 100,000 person-years of AIDS diagnoses (95% CI = 686-9723).
The age-adjusted incidence rate ofinvasive pneumococcal disease in Alaska Natives with no known underlying predisposing conditions was 29 per 100,000 persons but 46 per 100,000 persons for those with underlying diseases. For Alaska Natives without identified underlying predisposing diseases, the incidence rates for 2-to 4-year-olds and 5-to 9-year-olds were 64 and 13.8 per 100,000, respectively; the rate was lower for those 10-54 years of age but was 20.1 per 100,000 for those 55-64 years old.
Outcome. The age-adjusted mortality rate for all invasive pneumococcal disease was almost 5 times higher for Alaska Natives than for nonnatives and reflected markedly higher rates ofinfection for Alaska Native adults (table I) . Nineteen (79%) patient deaths in Alaska Natives and 18 (67%) in nonnatives were categorized as immediate. The cumulative mortality rate for invasive pneumococcal disease was almost 1% by age 75 for Alaska Natives but <0.3% for nonnatives.
The overall case-fatality rates were nearly identical for both Alaska Natives and nonnatives, including children <2 years of age (I %-2%) and adults (13%-14%). The highest case-fatality rates were for meningitis (18%). Only the casefatality rates for bacteremia with no focus of infection, 15% in Alaska Natives and 5% in non natives, were statistically different (P = .05). The case-fatality rates for Alaska Native adults with and without underlying conditions were 17% and 5%, respectively (P > .1).
A total of 51 patients (47 adults) died from pneumococcal infections, including 12 of the 23 Alaska Natives and at least 7 of24 non natives who were alcoholics (P = .20). From I to 48 months after their pneumococcal infections, 20 adults died from malignancies and 26 others died from chronic conditions (including AIDS in 3) that were present at the time of infection.
Impact ofpneumococcal disease. Years of productive life lost from invasive pneumococcal infections were 75 per 100,000 person-years for all Alaska Natives before age 65 but only 17 per 100,000 person-years for all nonnatives. For 
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meningitis isolates from nonnatives <2 years of age. Among patients> 19 years ofage, however, these 7 serotypes or serogroups accounted for only 32% of invasive pneumococcal isolates from Alaska Natives and 48% of those from nonnatives.
Vaccination rates in Alaska Natives. A history ofvaccination with pneumococcal polysaccharide before an invasive pneumococcal infection was ascertained for 27 (18%) of all cases in Alaska Natives> 19 years of age (n = 27), and only I of 10 serotypes identified was not included in the 23-valent vaccine. One-third of these persons were vaccinated~6 years earlier, and the mean interval from time of vaccination to infection was 4.4 years. Preexisting chronic diseases for which the pneumococcal vaccine is clearly indicated were identified in 109 adults with pneumococcal infection, but only 18 (17%) were vaccinated. Among Alaska Native patients~65 years of age, 15 (45%) were vaccinated before their infection. Only 2 of 10 Alaska Natives who experienced recurrent disease and were >4 years ofage at the time oftheir first infection were vaccinated before their second episode. Among Alaska Natives~2 years who died from disease due to pneumococcal serotypes in the current vaccine, 12 (55%) were vaccinated a mean of 4.6 years earlier, including 5 patients vaccinated~6 years previously. adults 20-64 years of age, 91 years of productive life were lost per 100,000 person-years for Alaska Natives but only 13 per 100,000 person-years were lost for nonnatives. The length of hospitalization for almost all (96%) inpatients with community-acquired disease ranged from I to 89 days, with a mean of 16 days for meningitis and 9 days for all other illnesses. Hospitalization exceeded 14 days for 1 of every 6 patients. For Alaska Natives, hospitalization was only slightly longer (mean, 9.9 days; median, 7) than for nonnatives (mean, 8.9; median, 6) (P > .1).
Serotype distributions. Details of serotype distribution in this population are presented elsewhere [21] . The 574 pneumococcal isolates were distributed among 36 different serotypes, and 94% are represented in the current 23-valent pneumococcal vaccine. Nine serotypes or serogroups-I, 4, 6, 7, 9, 12, 14, 18, and 19-accounted for 80% of the isolates for all ages. Type 14 was the most common infecting serotype in infants (31%) and second most common in adults (13%) after type 12F (15%).
Seven pneumococcal serotypes or serogroups (4, 6, 9, 14, 18, 19, 23) that have been suggested for inclusion in a prototype pneumococcal conjugate vaccine accounted for 85%of all invasive strains, including 63% of meningitis strains isolated from Alaska Natives and 90%of all strains and 75% of Discussion This study confirms that incidence and mortality rates of bacteriologically confirmed invasive pneumococcal disease among all age groups of Alaska Natives are 5-fold higher than among nonnatives. It extends previous observations that Alaska Natives have a high incidence of invasive pneumococcal disease regionally and pneumococcal endocarditis statewide [12, 13, 22] . This level of morbidity is 4-7 times higher than in most other western populations [5, 6, 8, 10, [17] [18] [19] 23 ]. The age-adjusted incidence for nonnative Alaskans, 92% of whom are white, is 1.2-1.5 times higher than contemporary rates for US whites [5, 11, 18] .
The childhood incidence of this disease merits specific attention. Incidence rates of all invasive pneumococcal disease among Alaska Native children <2 years ofage are 4-6 times higher than those in nonnative Alaskans and populations elsewhere in the United States [5, 18] ,6 times higher than the incidence recently reported from Finland [24] , and 13 times higher than the incidence in Israel [25] . The annualized incidence for pneumococcal meningitis in Alaska Native children <2 years of age is 8 times higher than the rates in nonnative Alaskans and 14 times higher than the rate for other US residents [26] . In rural southwest Alaska, the site of our surveillance report for 1980-1986 [12] , the attack rate for either pneumococcal meningitis or bacteremic pneumonia, I in 63 children by the age of2 years, remained identical during 1986-1990. This attack rate was 2-fold higher than that for Alaska Native children aged~2 years living else- where and 20 times the rate for nonnatives statewide despite access in southwest Alaska to parenteral ceftriaxone and, since 1989, bacterial polysaccharide immune globulin at birth. Although the incidence of invasive pneumococcal disease in Apache children in Arizona was higher (1820/ 100,000/year) [16] , this rate included no cases of meningitis and was based on a higher proportion of diagnoses ofbacteremia without a focus of infection.
The ratios of incidence rates of invasive pneumococcal infection among Alaska Natives to rates among other populations represent true differences in disease occurrence. When compared with contemporary rates established in a benchmark community, Charleston County, South Carolina [5] , rates for Alaska Natives were >3-fold higher for all age groups except those 10-19 years. The rates of invasive disease in Alaska Natives are an underestimate of the actual incidence of all pneumococcal disease, since blood cultures from patients with pneumococcal pneumonia are positive only 20%-30% of the time [27, 28] and cannot be obtained before empiric antibiotic therapy in most Alaskan villages. Since the proportion of cases detected only by retrospective review was similar for both Alaska Natives and nonnatives, any ascertainment bias was unlikely. Meningitis is a diagnosis likely to be completely and uniformly reported, and its higher incidence in Alaska Natives heralds higher rates for all invasive disease. In addition, we found comparable or higher proportions of radiographically confirmed pneumonia among Alaska Natives than in other population groups [5, 6, 10, 16, 24, 25] . The lower proportion of bacteremia without an identified focus of infection, along with its higher case-fatality rate in Alaska Natives compared with nonnatives, probably is due to a more virulent disease manifested by serotype differences [21] .
In addition to this report of the variable incidence ofinvasive pneumococcal disease in different ethnic groups living in geographic proximity, higher rates (unrelated to AIDS) have also been reported in US blacks and American Indians than in neighboring whites [5, 11, 16, 17] and in non-Jews than in Jews in Israel [25] . Only in Israel were differences ascribed to crowding and lower socioeconomic status.
The descriptive epidemiology of pneumococcal disease in Alaska provides few explanations for the ethnic differences in disease incidence. A summer nadir of disease occurred only for nonnatives in Alaska, characteristic of pneumococcal disease patterns in Finland [24] and in more moderate climates [15, 29] . Hence, our earlier speculation that increased outdoor exposure and extended socialization of Alaska Natives during the arctic summer promotes transmission of pneumococci [12] may explain why pneumococcal disease does not decline among Alaska Natives in warmer weather. Ethnic differences in the distribution of serotypes only partially explain the wider differences in disease incidence [21] .
Underlying preexisting medical conditions possibly explain the high incidence of pneumococcal disease in Alaska Natives. Underlying conditions were present in 35% of Alaska Native children <2 years ofage who had pneumococcal infections, a higher proportion than most other studies have reported (4%-29%) [5,9-11, 16,24,25] . Anemia and low birth weight did not precede invasive pneumococcal infections in young Alaska Native children statewide despite such findings in southwest Alaska [12] . Although the preva- lence of underlying conditions in 85% of Alaska Native adults with invasive disease is similar to other reports (54%-92%) [4.5.8-11. 16 ], the proportion with alcoholism (59%) was higher except for Apaches [16] . Although a high prevalence of invasive pneumococcal disease has been observed elsewhere in adults with AIDS [30] [31] [32] , the crude incidence rates of AIDS in Alaska Natives (2.7/100.000 person-years; 95% CI = 1.3-4.8) and nonnatives (3.3/100.000 personyears; 95%CI = 2.6-4.2) during the surveillance period were similar. The explanation for the high rates of pneumococcal disease in Alaska Natives may be found in a combination of unexplored social. genetic. and environmental factors. Compared with Alaskan whites. Alaska Natives have 2-fold higher fertility rates, fewer and later prenatal visits. and higher neonatal and postneonatal mortality [33] . Two separate gene markers have been identified in Alaskan Eskimo children with invasive Haemophilus infiuenzae type b disease, contributing about one-third of the attributable risk [34, 35] , but no similar search has been done in Alaska Native children with invasive pneumococcal disease. A clonal origin of multiresistant invasive serotype 6B pneumococci [36Jand a high nasopharyngeal carriage rate ( 13%)of phenotypically identical S. pneumoniae were reported in Alaska Native preschool children in the same community [37] . A higher proportion of Alaska Natives than nonnatives are current smokers [38] , up to 68% of women of childbearing age [39] ; in one community. 44% of preschool Alaska Native children had biochemical markers for recent tobacco smoke exposure [40] . This exposure. which enhances bacterial attachment [41] and is associated with respiratory infections [42] , explains in part the ethnic differences in pneumococcal disease.
That case-fatality rates for Alaska Natives and nonnatives with serious pneumococcal infections are almost identical (8%) is remarkable, given that many Alaska Natives live in remote locations and the proportion of cases of pneumococcal meningitis and pneumonia in Alaska Natives is higher. These overall case-fatality rates are relatively low compared with contemporary rates of 5%-33% elsewhere [5,6. 10. 11, 16-18] . However, the mortality rate in Alaska Natives. which is 5-fold higher than that of nonnatives, and their 7-fold higher number ofyears of productive life lost more accurately reflect the impact of pneumococcal infections.
Although the serotypes responsible for invasive disease in Alaskan infants appear well suited to pneumococcal conjugate vaccines under development, the levels of disease reported here merit consideration of other preventive modalities currently available. Bacterial polysaccharide immune globulin may prevent up to 80% of bacteremic pneumococcal disease during the first 2 years of life if it is administered regularly [43] (Santosham M. personal communication). Al- though the 23-valent polysaccharide vaccine is generally not considered immunogenic or efficacious in infants [44, 45] , in Papua New Guinea, where a decline of maternally acquired antibody occurs before acquisition ofnatural immunity [46] , IgG levels increased severalfold in response to vaccination [47] . This is considered responsible for a reduction in childhood mortality and morbidity following vaccination with the 23-valent pneumococcal vaccine [48, 49] . One of every six invasive pneumococcal infections in preschool Alaska Native children occurs in 2-to 4-year-olds, whose disease incidence is more than 3-fold higher than among nonnative toddlers. The ethnic variation of infant responses to both H. influenzae type b and pneumococcal polysaccharides [50, 51] supports a reconsideration of the 23-valent vaccine for Alaska Native toddlers until a safe and efficacious conjugate vaccine is available. The prevention of fatal pneumococcal disease in Alaska Native adults is imperative; the specter of multi antimicrobial resistance in this population is growing [21, 37] . The current 23-valent pneumococcal polysaccharide vaccine remains the most appropriate immunogen for adults, since it is unlikely that any conjugate vaccine will include more than one-third ofthe serotypes present in the former. One conjugate vaccine now under development will include serotypes responsible for only 32% of invasive adult infections in Alaska Natives, largely because of its exclusion of serogroup 12.
Although the 23-valent pneumococcal vaccine includes 94% of the invasive serotypes identified in Alaska Native adults, it remains underused. Relatively few vaccinations were received by Alaska Native adults with invasive infections, either before or after their episode, despite a high recurrence rate and high proportion of patients with underlying conditions that clearly justified vaccination. Most important, the incidence of invasive pneumococcal disease without identified underlying conditions in Alaska Natives of several age groupings exceeds the threshold of disease that originally justified vaccinating the healthy elderly [17, 23, 52] . The reduction of pneumococcal disease in Alaska Native adults will require a broader application of the 23-valent pneumococcal polysaccharide vaccine than currently practiced.
